The back-to-back arguments on tirzepatide, the active ingredient in Eli Lillys Mounjaro and Zepbound, and the related semaglutide case, Novo Nordisks Ozempic and Wegovy, boiled down to two questions: Did the FDA follow the right procedure, and did it actually look at the facts fairly
Although Ozempic, Mounjaro, and Rybelsus are not FDA-approved for obesity treatment, they are included in the analysis due to the high number of patients with an obesity diagnosis using these products compared to other FDA-approved Type 2 diabetes GLP-1 agonists
Hepatitis B
There have even been suggestions that plan sponsors consider implementing lifetime maximums on obesity drugs
It is highly unlikely a TUE would be approved for Sermorelin, as it is not a first-line treatment for growth hormone deficiency and there are alternative treatments available
This therapy supports respiratory health by delivering targeted nutrients and antimicrobials directly to your lungs